A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumours

Trial Profile

A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Alpelisib (Primary) ; Binimetinib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2016 Results of phosphoprotein analysis in patients from the Extension Arm 4A of this trial (n=6), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017.
    • 26 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top